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A B S T R A C T
Several clinical and epidemiological studies revealed increased bone turnover and lower bone mass in patients with
urolithiasis. Bone mass loss is particularly evident in idiopathic calcium stone formers. However, pathogenetic mecha-
nisms and factors implicated in bone loss in these patients are still unknown. Dietary calcium restriction, increased in-
take of salt and animal proteins, vitamin D receptor polymorphisms are likely risk factors, while role of inflammatory
cytokines, osteopontin and prostaglandin mediated bone resorption is yet to be determined. Regarding treatment and
prevention, it has been proven that calcium supplements and high calcium diet with the addition of potassium alkali
have an important role in prevention and treatment of both, urolithiasis and osteoporosis. Thiazide diuretics reduce
hypercalciuria in renal tubules, and in addition promote osteoblast differentiation. Finally, bisphosphonates, a com-
monly used drugs in treatement of osteoporosis, show the potential to inhibit calcium stone formation, whereas a possible
protective effect of antioxidants in bone loss and renal injurie needs to be investigated further.
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Introduction
Urolithiasis is one of the leading social and economi-
cal problems of modern society. It is estimated that in de-
veloped countries, 10% of males and 4 % of females be-
tween 30 and 50 years of age have urinary tract stone
disease. The major problem presents recurrence rate of
urolithiasis which is 75% at 15 years with no treatment1.
Clinical manifestations are characterized by lumbar pain
of sudden onset that may be accompanied by nausea and
vomiting, gross or microscopic hematuria2. Diagnosis of
renal stone is performed by urinalysis and imaging. Uri-
nalysis often reveals hematuria, while crystalluria is oc-
casional and the presence of leucocyturia may suggest as-
sociated urinary tract infection. Since renal ultrasound
(US) provides information about obstruction but may
miss ureteral stones, the association of US with conven-
tional abdominal X-ray may help3. Stone formation is
usually a result of urinary supersaturation and lack of in-
hibitors of crystallization in urine4. Calcium is the major
calculus component since 75–80% of renal stones is com-
posed of calcium oxalate5, while idiopathic metabolic
hypercalciuria is one of the most frequent causes of re-
current calcium urolithiasis6,7. Numerous studies sho-
wed that urolithiasis patients have higher rate of bone
resorption and lower bone mineral content as well as
bone mineral density, which is more evident in idiopathic
calcium stone formers8–10. Exact pathogenetic mecha-
nisams of low bone mineral density in calcium stone
formers are still not defined. Since osteoporosis, as well
as urolithiasis, has a huge effect on public health because
of the impact of osteoporotic fractures on the health ser-
vice and economy with prevalence between 10 and 15
percent11 it is very important to define common preven-
tion and treatment guidelines.
Possible Pathogenetic Mechanisams
of Bone Loss in Urolithiasis Patients
Hypercalciuria could be defined as any level of urine
calcium that exceeds net intestinal absorption, leading to
net loss of calcium. In practice, this is usually defined as
a daily calcium excretion over 250 mg/day in women or
300 mg/day in men6. Idiopathic hypercalciuria (IH) is de-
fined as excess calcium excretion in spite of normal or re-
stricted calcium intake with no identifiable metabolic
cause, while dietary calcium-dependent hypercalciuria
(DH) is caused by an excessive intake of calcium12. Pa-
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tients with IH have sometimes been categorized by the
presumed site of the primary abnormality. The major
subtypes have included 1) 'absorptive' hypercalciuria in
which a primary increase in intestinal calcium absorp-
tion may result in increased urine calcium; 2) fasting
resorptive hypercalciuria, caused by an increase in bone
turnover, leading to loss of bone calcium in the urine; and
3) 'renal leak' hypercalciuria, in which a primary defect
in renal tubule calcium transport allows loss of calcium
in the urine, with compensatory increase in calcium ab-
sorption from gut or mobilization from bone13. Nearly
90% of patients with idiopathic hypercalciuria have met-
abolic alterations that could lead to bone mass reduction
and osteoporosis8,10,14–16. However, some studies did not
find any influence of this metabolic alteration on bone
mass17 which could be explained by lack of significant
differencies in BMD between control subjects and pa-
tients with absorptive hypercalciuria. In fact, several au-
thors have shown that fasting hypercalciuria and not ab-
sorptive hypercalciuria is linked with reduced bone min-
eral density18,19. From the aspect of bone formation pro-
cess, lower bone mass in urolithiasis patients may be
caused by increased bone resorption and/or decreased
bone formation. Hydroxyprolinuria, a known marker of
bone resorption, is higher in IH than in DH and is corre-
lated with fasting calciuria, suggesting that hypercalciu-
ria in these patients is linked to bone resorption18. Histo-
morphometric studies on hypercalciuric stone formers
showed reduced osteoblastic bone formation with or with-
out increased osteoclastic bone resorption, severe miner-
alization defect consistent with normal or low bone turn-
over osteoporosis9. Malluche et al. observed reduced osteo-
blastic formation of bone matrix and delayed or absent
secondary mineralization20.
Secondary hyperparathyroidism is extremly rare in
IH patients who have mainly normal or low values of
plasma parathormone (PTH)21, indicating that a PTH-
-independent mechanism is responsible for bone demin-
eralization in these patients.
Increased levels of serum calcitriol observed in IH
patients22,23 are not responsible for bone loss in IH pa-
tients since there is a positive correlation between plas-
ma 1.25(OH)2 vitamin D3 levels and BMD23.
Many genetic studies investigated an association be-
tween vitamin D receptor (VDR) polymorphisms and cal-
cium kidney stone disease. Rendina et al.24 demonstrated
a genetic association between 3’ VDR alleles, fasting idio-
pathic calciuria, and reduced bone mass density in pa-
tients with recurrent stone formation, whereas other au-
thors showed that patients with VDR polymorphism had
a significantly higher risk of having more stone episodes at
younger age although it was not associated with the forma-
tion of stones25,26. In those studies stone forming patients
were not randomised for fasting and absorptive idio-
pathic calciuria which could explain given discrepancies.
A diet rich in animal proteins has been implicated in
producing bone loss through a variety of mechanisms.
Metabolic acidosis caused by protein rich diet induces
bone dissolution releasing calcium to act as a buffer7,27
and increase in renal mass and calcitriol levels28, which
then consequently lead to hypercalciuria and bone loss.
Also, acidosis is proven to inhibit osteoblastic and stimu-
late osteoclastic activity in vitro29.
Low calcium diet which is oftenly used to treat renal
calculi could cause low BMD in urolithiasis patients. Cal-
cium intestinal absorption declines with age while re-
quirements rises which in the combiation with low cal-
cium intake induces bone loss through PTH stimulated
increase in bone remodeling. Furthermore, reduction of
the calcium supply increases the oxalate absorption, en-
hances urinary saturation for oxalate salts which ex-
plains why low-calcium diet increases the risk of calcium
oxalate stone formation30.
The identification of the RANKL/RANK (receptor ac-
tivator for nuclear factor kappaB (RANK) ligand) signal-
ing system as the dominant, final mediator of osteo-
clastogenesis represents a major advance in bone biology.
RANKL, expressed on the surface of preosteoblastic/stro-
mal cells, binds to RANK on the osteoclastic precursor
cells, therefore initiating process of differentiation and
fusion of osteoclast precursors and stimulate activity of
mature osteoclasts31. Osteoprotegerin (OPG), member of
TNF (tumor necrosis factor receptor) family, acts as a de-
coy receptor, binding RANKL and consequently blocking
RANK-RANKL interaction and therefore inhibits osteo-
clastogenesis32. Influence of RANKL/OPG system on bo-
ne turnover in patients with urolithiasis remains yet to
be investigated, although latest research demonstrated
higher expression of RANKL in bone tissue in patients
with idiopathic hypercalciuria suggesting that increased
bone resorption is mediated by RANKL, while osteopro-
tegerin bone expression was probably secondarily in-
creased to counteract the actions of RANKL33.
Pro-inflammatory cytokines such as interleukin-1
(IL-1), interleukin-6 (IL-6) and tumor necrosis factor-al-
pha (TNF-a) supress OPG expression while simulta-
neously enhancing that of RANKL resulting in increased
osteoclast formation and function. Pacifici et al.19 demon-
strated that increased production of interleukin-1 (IL-1) by
cultured peripheral blood monocyte is associated with
decreased vertebral BMD in patients with fasting hyper-
calciuria. IL-1 can provoke bone resorption through os-
teoblasts, which are induced to transmit a signal that
stimulates osteoclasts34 and through a prostaglandine
dependent mechanism35. In addition, prostaglandine sti-
mulate calcitriol synthesis36. Thus, in idiopathic hyper-
calciuria the increased bone resorption and/or decreased
bone formation leading to reduction of bone mass and
the high plasma calcitriol level could result from activa-
tion of monocytes and the synthesis of IL-1. Considering
that other cytokines like TNF-a37,39 and IL-640 have bone
catabolic effect, that granulocyte macrophage stimulat-
ing factor (GM-CSF) synthesis is induced by IL-1 and
TNF-a41, and that this factor contributes to prolifera-
tion, survival and differentiation of osteoclasts42,43 and
osteoblasts44, it can be concluded that cytokine activation
may be involved in the bone loss of calcium stone formers
with IH45.
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It is well known that in urinary stone formation pro-
cess pre-urine CaOx supersaturation triggers inflamma-
tion in the long Henle’s loop cells. This in turn induces
differentiation of these cells toward the osteogenic lin-
eage, determining the synthesis of typical bone osteoid
proteins (osteopontin, osteocalcin, BMP-2, etc)46. In the
normal rat kidney, osteopontin has been shown to be lo-
calized precisely in the Golgi apparatus of the thin loop of
Henle’s loop cells. It is a strong inhibitor of crystal for-
mation and growth in vitro, but there is still debate re-
garding its effects upon crystal adhesion to tubular epi-
thelial cells46. OPN influences bone turnover, both by
promoting differentiation of osteoclasts and by enhanc-
ing osteoclasts activity. Moreover, osteopontin is a potent
inhibitor of the mineralization process, since binding of
OPN to hydroxypatite (HA) inhibits growth of HA cry-
stals47. As OPN promotes calcium stone formation and
bone catabolism, it could play an important role in bone
mass decrease in urolithiasis patients.
Prevention and Treatment – Common
Guidelines in Urolithiasis and Osteoporosis
Patients
Calcium supplements and high calcium intake are
widely used for the prevention of bone loss in postmeno-
pausal women, but they potentially enhance the risk of
calcium oxalate stone formation by increasing urinary
calcium. The abnormal parathyroid secretory phisiology,
high circulating PTH levels an elevated markers of bone
resorption are all reversible with a high calcium intake48,
whereas calcium supplementation reduces both bone loss
and fracture rate in the elderly49,50. Sakhaee et al.51 dem-
onstrated that calcium citrate supplementation may be
provided to stone-free postmenopausal women without
fear of increased risk of stone formation.
As pointed earlier, protein rich diet induces bone loss
as well as hypercalciuria due to metabolic acidosis. Ad-
ministration of potassium citrate by providing an alkali
load may avert the bone resorbing effect of acid excess52.
It has also been shown that potassium alkali avert recur-
rent stone formation in a mixed group of patients with
idiopathic calcium oxalate nephrolithiasis53. Therefore,
the addition of potassium citrate among postmenopausal
women with urolithiasis, would be reasonable since it re-
duces urinary saturation of calcium oxalate and provides
greater inhibitor activity against stone formation from
further enhancement of citrate excretion51.
Thiazide diuretics, widely used in hypercalciuric pa-
tients, lower urine calcium resulting in a fall in calcium
oxalate and calcium phosphate supersaturation. Reduc-
tion of calciuria is attributed to enhanced reabsorption of
calcium on the renal distal convolute tubule54. Also, latest
sudies showed that thiazides directly induce the produc-
tion of the osteoblast differentiation markers runt-re-
lated transcription factor 2 (runx2) and osteopontin,
therefore stimulating osteoblast differentiation and bone
mineral formation independent of their effects in the
kidney. These results suggest that thiazides may find a
role in the prevention and treatment of osteoporosis55.
It is well known that hyperoxaluria induces free radi-
cal generation which results in peroxidative injury in re-
nal tubular cells. This can lead to calcium deposition and
nephrolithiasis56. Many studies have shown that various
antioxidants, such as vitamin E and green tea, could
have protective effect on renal epithelium and prevent
crystal deposition57,58. Also, nitrosative stress is consid-
ered to be an important risk factor in urolithiasis, which
would mean that L-arginin, a precursor of nitric oxide
(NO) should have antilithic and antioxidative proper-
ties59. Furthermore, increased osteoclastic activity and
decreased osteoblastic activity are associated with an im-
balance between oxidant and antioxidant status in post-
menopausal osteoporosis60 suggesting that antioxidant
reach diet, as well as other antioxidants (NO, caroten-
oids) could be used in bone loss prevention and treat-
ment of osteoporosis61,62.
Bisphosphonates are one of the most common used
drugs in treatment of osteoporosis. They reduce osteo-
clast-mediated bone resorption by enhancing program-
med cell death and inhibiting enzymes in the cholesterol
biosynthetic pathway causing slower bone turnover. They
have proven efficacy for prevention of bone loss caused
by aging, estrogen deficiency, and glucocorticoid use and
for prevention of fracuters in postmenopausal women
and in women and men with glucocorticoid induced
osteoporosis63. Recent study performed on healthy males
during 90-day bed rest which has potential risks of bone
loss and renal stone formation, showed that intravenous
pamidronate could preserve bone mineral density and re-
duce the risk of renal stone formation during prolonged
bed rest64. Also, in vitro studies performed on Madin-
-Darby canine kidney (MDCK) cells investigated the in-
hibitory effects of alendronate on calcium phosphate
microlith formation. The results demonstrated that alen-
dronate inhibited calcium stone formation, suggesting
that it could be effective in the prevention of urolithiasis65.
In conclusion, it has been clearly demonstrated that
disorders of mineral metabolism responsible for lower
bone mineral density are present in patients with idio-
pathic hypercalciuria ultimately leading to osteopenia/
osteoporosis. Furthermore, high calcium intake and al-
kali load have benefitiary effect in prevention and treat-
ment of renal stone disease and osteoporosis, while the
effect of bisphosphonates on calcium stone formation
and protective role of antioxidants and thiazides in osteo-
porosis remains to be determined.
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UROLITIJAZA I OSTEOPOROZA: KLINI^KA VA@NOST I TERAPIJSKE SMJERNICE
S A @ E T A K
Nekoliko klini~kih i epidemiolo{kih studija pokazale su pove}anu ko{tanu pregradnju i manju ko{tanu masu u pa-
cijenata s urolitijazom. Gubitak ko{tane mase posebno je vidljiv kod idiopatske kalcijske urolitijaze. Ipak, patogeneza i
~imbenici uklju~eni u proces gubitka ko{tane mase jo{ nisu poznati. Mogu}i rizi~ni ~imbenici su ograni~en unos kalcija,
pove}an unos soli i bjelan~evina `ivotinjskog podrijetla te polimorfizmi za receptor vitamina D, dok se uloga upalnih
citokina, osteopontina i prostaglandina u razgradnji kosti tek treba utvrditi. Dokazano je da preparati kalcija te dijeta s
visokim unosom kalcija s dodatkom kalijevih soli imaju va`nu ulogu u preveciji i lije~enju i urolitijaze i osteoporoze.
Tiazidski diuretici smanjuju hiperkalciuriju u bubre`nim tubulima i poti~u diferencijaciju osteoblasta. Kona~no, postoji
mogu}nost da bifosfonati, koji se ~esto primjenjuju u lije~enju osteoporoze inhibiraju stvarnje kalcijskih kamenaca, dok
je mogu}i za{titni u~inak antioksidansa na gubitak ko{tane mase i o{te}enje bubre`nog epitela potrebno dodatno istra`iti.
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